drugset / Trial / NCT00830414

Medroxyprogesterone Acetate Injection 150 mg/1 mL in Postmenopausal Women

NCT00830414

Phase 1 Completed 124 enrolled Teva Pharmaceuticals USA
RandomizedParallel-groupOpen-labelOther

Summary

This study compared the rates and extents of medroxyprogesterone absorption from two medroxyprogesterone acetate injection formulations following single 150 mg intramuscular (IM) injections to healthy postmenopausal women.

Timeline

Start
2002-04
Primary completion
2002-09
Completion
2002-09

Drugs

EvaluationDrugModalityDoseRoute
Comparator medroxyprogesterone acetate Other / unclassified 150 mg Intramuscular

Indications

No indication recorded.